Latest Ratios: P/E Ratio 12.9x · EV/EBITDA 9.9x · ROE 10.2%. (2001–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.4B | $2.9B | $4.3B | $3.6B | $3.1B | $2.7B | $2.2B | $1.9B | $1.6B | $1.8B | $3.0B |
| Enterprise Value | $3.4B | $3.9B | $5.3B | $4.7B | $4.4B | $4.2B | $3.7B | $3.5B | $3.3B | $3.8B | $5.1B |
| P/E Ratio → | 12.90 | 15.16 | 20.04 | 17.40 | — | 13.10 | 13.56 | 13.19 | — | 5.32 | 42.74 |
| P/S Ratio | 2.19 | 2.65 | 3.78 | 3.24 | 2.77 | 2.48 | 2.36 | 1.95 | 1.60 | 1.73 | 3.36 |
| P/B Ratio | 1.30 | 1.53 | 2.35 | 2.20 | 2.16 | 1.71 | 1.64 | 1.60 | 1.42 | 1.53 | 3.60 |
| P/FCF | 9.40 | 11.36 | 17.70 | 15.21 | 14.08 | 10.75 | 10.45 | 9.26 | 8.71 | 9.14 | 20.48 |
| P/OCF | 9.00 | 10.88 | 17.12 | 14.63 | 13.60 | 10.36 | 9.47 | 8.64 | 8.23 | 8.59 | 20.06 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.55 | 4.62 | 4.21 | 3.93 | 3.84 | 3.94 | 3.68 | 3.41 | 3.62 | 5.80 |
| EV / EBITDA | 9.89 | 11.36 | 14.31 | 12.69 | 434.20 | 11.52 | 11.34 | 10.79 | 33.52 | 15.10 | 22.11 |
| EV / EBIT | 10.89 | 12.51 | 15.83 | 13.79 | — | 12.76 | 12.96 | 12.33 | 49.66 | 11.68 | 25.03 |
| EV / FCF | — | 15.22 | 21.59 | 19.78 | 19.98 | 16.66 | 17.40 | 17.51 | 18.61 | 19.06 | 35.34 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8% | 52.8% | 55.8% | 55.5% | 55.4% | 57.1% | 58.0% | 57.3% | 56.9% | 55.4% | 56.7% |
| Operating Margin | 28.4% | 28.4% | 29.6% | 30.4% | -2.0% | 30.4% | 31.5% | 30.2% | 6.9% | 20.7% | 23.3% |
| Net Profit Margin | 17.5% | 17.5% | 18.9% | 18.6% | -7.3% | 18.9% | 17.5% | 14.8% | -3.7% | 32.6% | 7.9% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.2% | 10.2% | 12.3% | 13.5% | -5.4% | 14.0% | 13.0% | 12.6% | -3.1% | 33.9% | 8.9% |
| ROA | 5.5% | 5.5% | 6.4% | 6.3% | -2.3% | 5.8% | 4.7% | 4.1% | -1.0% | 8.9% | 2.0% |
| ROIC | 8.2% | 8.2% | 9.1% | 9.3% | -0.6% | 8.4% | 7.8% | 7.6% | 1.7% | 5.3% | 5.8% |
| ROCE | 9.2% | 9.2% | 10.4% | 10.7% | -0.7% | 9.7% | 8.9% | 8.7% | 1.9% | 5.8% | 6.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.55 | 0.55 | 0.57 | 0.69 | 0.94 | 0.95 | 1.12 | 1.51 | 1.64 | 1.69 | 2.67 |
| Debt / EBITDA | 3.07 | 3.07 | 2.85 | 3.05 | 133.90 | 4.16 | 4.62 | 5.37 | 18.12 | 7.99 | 9.48 |
| Net Debt / Equity | — | 0.52 | 0.52 | 0.66 | 0.90 | 0.94 | 1.09 | 1.43 | 1.62 | 1.66 | 2.62 |
| Net Debt / EBITDA | 2.88 | 2.88 | 2.58 | 2.93 | 128.17 | 4.09 | 4.53 | 5.08 | 17.84 | 7.86 | 9.30 |
| Debt / FCF | — | 3.86 | 3.89 | 4.57 | 5.90 | 5.91 | 6.95 | 8.25 | 9.91 | 9.92 | 14.86 |
| Interest Coverage | 7.31 | 7.31 | 6.97 | 5.11 | -0.36 | 5.08 | 3.48 | 2.98 | 0.64 | 3.03 | 2.18 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.57 | 3.57 | 4.20 | 3.20 | 2.44 | 2.04 | 2.21 | 2.44 | 2.37 | 2.46 | 2.06 |
| Quick Ratio | 2.25 | 2.25 | 2.82 | 2.02 | 1.43 | 1.21 | 1.27 | 1.67 | 1.43 | 1.50 | 1.35 |
| Cash Ratio | 0.53 | 0.53 | 0.92 | 0.40 | 0.36 | 0.19 | 0.26 | 0.63 | 0.22 | 0.26 | 0.26 |
| Asset Turnover | — | 0.31 | 0.33 | 0.34 | 0.34 | 0.30 | 0.28 | 0.27 | 0.28 | 0.28 | 0.23 |
| Inventory Turnover | 3.23 | 3.23 | 3.41 | 3.61 | 3.10 | 3.87 | 3.44 | 3.54 | 3.51 | 3.92 | 3.30 |
| Days Sales Outstanding | — | 64.34 | 62.33 | 57.34 | 54.06 | 46.79 | 44.37 | 57.05 | 55.66 | 49.39 | 56.58 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.8% | 6.6% | 5.0% | 5.7% | — | 7.6% | 7.4% | 7.6% | — | 18.8% | 2.3% |
| FCF Yield | 10.6% | 8.8% | 5.7% | 6.6% | 7.1% | 9.3% | 9.6% | 10.8% | 11.5% | 10.9% | 4.9% |
| Buyback Yield | 6.5% | 5.4% | 1.2% | 0.7% | 1.6% | 0.0% | 0.5% | 3.0% | 3.2% | 0.1% | 0.0% |
| Total Shareholder Yield | 6.5% | 5.4% | 1.2% | 0.7% | 1.6% | 0.0% | 0.5% | 3.0% | 3.2% | 0.1% | 0.0% |
| Shares Outstanding | — | $49M | $50M | $50M | $50M | $51M | $51M | $51M | $52M | $54M | $53M |
Persistent organic revenue decline
Based on current market data, PBH trades at a forward P/E of 10.89, which represents a significant discount to peers like Kenvue and Haleon, suggesting that investors are pricing in a terminal decline rather than a recovery in the company's core OTC brand portfolio performance.
The current valuation multiple appears to reflect deep skepticism regarding the company's ability to return to organic growth. While the low P/E might appear attractive, it warrants caution as it may be a value trap if the underlying brand equity continues to erode against private-label competition.
As reported in financial statements, PBH's ROIC has remained stagnant, hovering near 2.0% in 2026Q4, which indicates that the company's heavy reliance on acquired intangible assets is failing to generate meaningful incremental returns on the capital deployed into its brand aggregation strategy.
The low ROIC suggests that the cost of acquiring new brands may be outpacing the cash flow benefits they provide. Investors should monitor whether management can improve capital allocation efficiency, as the current trend implies that the company is struggling to compound value effectively.
According to recent quarterly filings, the cash conversion cycle has expanded to 143 days in 2026Q4, driven largely by elevated inventory days of 103, which suggests that the company is holding excess stock that may be difficult to move in a softening retail environment.
The lengthening CCC indicates potential inefficiencies in inventory management or a buildup of slow-moving stock. This trend warrants further investigation, as it may signal that the company's distribution model is becoming less responsive to actual consumer demand at the point of sale.
Based on reported figures, PBH has successfully reduced its debt-to-equity ratio to 0.55, a notable improvement from previous periods, which provides the company with a more comfortable buffer to service its obligations despite the ongoing headwinds in top-line revenue growth and market share.
The reduction in leverage appears to be a defensive move to preserve balance sheet health during a period of contraction. While this improves the risk profile, it also raises questions about whether the company has the capacity or appetite to pursue future growth-oriented acquisitions.
The P/E ratio is frequently misapplied to PBH because it ignores the significant non-cash amortization charges associated with the company's massive intangible asset base, which artificially depresses reported earnings and obscures the true cash-generative capacity of its niche consumer healthcare brand portfolio.
Analysts should prioritize P/FCF or EV/EBITDA over P/E to better understand the company's operational performance. Relying on P/E may lead to an incorrect assessment of the company's valuation, as it fails to account for the high cash conversion inherent in the asset-light business model.
Includes 30+ ratios · 26 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PBH stock.
Prestige Consumer Healthcare Inc.'s current P/E ratio is 12.9x. The historical average is 19.3x. This places it at the 11th percentile of its historical range.
Prestige Consumer Healthcare Inc.'s current EV/EBITDA is 9.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.7x.
Prestige Consumer Healthcare Inc.'s return on equity (ROE) is 10.2%. The historical average is 6.0%.
Based on historical data, Prestige Consumer Healthcare Inc. is trading at a P/E of 12.9x. This is at the 11th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Prestige Consumer Healthcare Inc. has 52.8% gross margin and 28.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Prestige Consumer Healthcare Inc.'s Debt/EBITDA ratio is 3.1x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.